MK-8353 hydrochloride
Modify Date: 2024-12-04 01:14:58
MK-8353 hydrochloride structure
|
Common Name | MK-8353 hydrochloride | ||
|---|---|---|---|---|
| CAS Number | 1951448-73-9 | Molecular Weight | 728.313 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C37H42ClN9O3S | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of MK-8353 hydrochlorideMK-8353 hydrochloride (SCH-900353) is a highly potent, orally bioavailable, dual-specificity ERK1/2 inhibitor with IC50 of 23.0/8.8 nM, respectively; inhibits nonactivated ERK2 with IC50 of 0.5 nM, demonstrates excellent kinase selectivity over a 227-human kinase panel; decreases pERK1, pERK2, and ribosomal S6 kinase (pRSK) proteins, with complete suppression of pERK1 and pERK2 observed at 30 nM in A2058 cells, inhibits the in vitro proliferation of a panel of BRAFV600-mutant and RAS-mutant cancer cell lines; exhibits in vivo antitumor activity against BRAFV600 mutant Colo-205 colon cancer model and the BRAFV600 mutant SK-MEL-28 melanoma model. Colon Cancer Phase 1 Clinical |
| Name | MK-8353 hydrochloride |
|---|
| Description | MK-8353 hydrochloride (SCH-900353) is a highly potent, orally bioavailable, dual-specificity ERK1/2 inhibitor with IC50 of 23.0/8.8 nM, respectively; inhibits nonactivated ERK2 with IC50 of 0.5 nM, demonstrates excellent kinase selectivity over a 227-human kinase panel; decreases pERK1, pERK2, and ribosomal S6 kinase (pRSK) proteins, with complete suppression of pERK1 and pERK2 observed at 30 nM in A2058 cells, inhibits the in vitro proliferation of a panel of BRAFV600-mutant and RAS-mutant cancer cell lines; exhibits in vivo antitumor activity against BRAFV600 mutant Colo-205 colon cancer model and the BRAFV600 mutant SK-MEL-28 melanoma model. Colon Cancer Phase 1 Clinical |
|---|---|
| References | References 1. Moschos SJ, et al. JCI Insight. 2018 Feb 22;3(4). pii: 92352. View Related Products by Target ERK Colon Cancer |
| Molecular Formula | C37H42ClN9O3S |
|---|---|
| Molecular Weight | 728.313 |